Decision: Favourable
Study Title:
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined with Domvanalimab (AB154) Compared to Pembrolizumab in Front-Line, PD-L1- High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NREC Code:
23-NREC-CT-023
Decision:
Favourable
Meeting Date:
24/03/2023
Study Type:
CT application
Principal Investigator:
Dr. Jarushka Naidoo
PI Institution:
Beaumont Hospital
Sponsor:
Arcus Biosciences, Inc.